-
EP4081117
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4081117
| EP4081117 - CONNECTED DRUG DELIVERY SYSTEM FOR ERYTHROPOIETIN STIMULATING AGENTS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 30.09.2022 Database last updated on 06.11.2024 | |
| Former | The international publication has been made Status updated on 07.07.2021 | ||
| Former | unknown Status updated on 12.10.2020 | Most recent event Tooltip | 19.09.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Fresenius Medical Care Holdings, Inc. 920 Winter Street Waltham, MA 02451 / US | [2022/44] | Inventor(s) | 01 /
YUDS, David c/o Fresenius Medical Care North America 4040 Nelson Ave. Concord, CA 94520 / US | 02 /
PEESAPATI, Sameer c/o Fresenius Medical Care North America 4040 Nelson Ave. Concord, CA 94520 / US | [2022/44] | Representative(s) | Freischem & Partner Patentanwälte mbB Salierring 47-53 50677 Köln / DE | [2022/44] | Application number, filing date | 20785628.7 | 16.09.2020 | [2022/44] | WO2020US51060 | Priority number, date | US201962952828P | 23.12.2019 Original published format: US 201962952828 P | [2022/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021133440 | Date: | 01.07.2021 | Language: | EN | [2021/26] | Type: | A1 Application with search report | No.: | EP4081117 | Date: | 02.11.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 01.07.2021 takes the place of the publication of the European patent application. | [2022/44] | Search report(s) | International search report - published on: | EP | 01.07.2021 | Classification | IPC: | A61B5/145, A61B5/0205, A61B5/021, A61B5/024, A61K38/18, A61B5/00, G01L1/16, A61M37/00, A61M5/158, A61B5/1455 | [2022/44] | CPC: |
A61B5/14503 (EP);
A61M5/14248 (EP,US);
A61B5/0205 (EP);
A61B5/021 (EP);
A61B5/02416 (EP);
A61B5/4839 (EP);
A61B5/6824 (EP);
A61B5/6833 (EP);
A61K38/1816 (EP);
A61M5/1409 (EP);
A61M5/1723 (US);
G01L1/16 (EP);
G01L1/18 (EP);
G16H20/17 (EP,US);
G16H40/67 (EP);
G16H80/00 (EP);
A61B2505/07 (EP);
A61B2560/0412 (EP);
A61B2560/0468 (EP);
A61B2562/0233 (EP);
A61B2562/0261 (EP);
A61B2562/164 (EP);
A61B5/0002 (EP);
A61B5/14535 (EP);
A61B5/1455 (EP);
A61M2005/14208 (US);
A61M2005/14252 (EP,US);
A61M2005/1726 (US);
A61M2202/0433 (US);
A61M2205/3327 (US);
| C-Set: |
A61K38/1816, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/44] | Title | German: | VERBUNDENES ARZNEIMITTELABGABESYSTEM FÜR ERYTHROPOIETINSTIMULIERENDE MITTEL | [2022/44] | English: | CONNECTED DRUG DELIVERY SYSTEM FOR ERYTHROPOIETIN STIMULATING AGENTS | [2022/44] | French: | SYSTÈME D'ADMINISTRATION DE MÉDICAMENT CONNECTÉ POUR DES AGENTS DE STIMULATION DE L'ÉRYTHROPOÏÉTINE | [2022/44] | Entry into regional phase | 28.03.2022 | National basic fee paid | 28.03.2022 | Designation fee(s) paid | 28.03.2022 | Examination fee paid | Examination procedure | 28.03.2022 | Examination requested [2022/44] | 28.03.2022 | Date on which the examining division has become responsible | 06.02.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 21.09.2022 | Renewal fee patent year 03 | 20.09.2023 | Renewal fee patent year 04 | 19.09.2024 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XYI]WO2009079589 (NEW WORLD PHARMACEUTICALS LLC [US], et al); | [A]US8348922 (IMRAN MIR [US]); | [Y]WO2015187802 (AMGEN INC [US]); | by applicant | US2010292632 | US2014074062 | US8939928 | US2017056585 | US2017157329 | US2019015581 | US2019091457 | US2019214967 | US2019254541 | US2019269862 |